Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LMI 1195-101 · 1 trial · 1 indication
Number of study subjects exhibiting treatment-related adverse events
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Healthy Population |
| Cohort 2 | EXPERIMENTAL | Heart Failure Subjects with a documented ejection fraction of 35% or less, and a diagnosis of NYHA Class II-III heart failure, history of ventricular arrhythmia and ICD placement |
| Name | Type | Description |
|---|---|---|
| LMI 1195-101 | DRUG | Single dose, bolus IV injection of LMI 1195 |
Cohort 1 Inclusion: * Healthy, age 18-40 Cohort 1 Exclusion: * Significant or chronic medical illness * Pregnant females * Smoking within one month of enrollment * Use of any prescription drugs within 4 weeks prior to dosing Cohort 2 Inclusion: * 30-70 year old subjects with a diagnosis of NYHA...
Top 20 of 31 competitors
LMI 1195-101 is an investigational small molecule being studied for use in heart failure. It is a cardiovascular therapeutic agent currently in Phase 1 clinical development. The drug is being evaluated for its safety, biodistribution, and dosimetry in patients with heart failure.
LMI 1195-101 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker LNTH. The company is conducting clinical research on this investigational cardiovascular drug for heart failure.
LMI 1195-101 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities. A Phase 1 trial has been completed to evaluate its safety and other early-stage characteristics in healthy subjects and heart failure patients.
LMI 1195-101 has one completed clinical trial, registered as NCT00891241. This Phase 1 study evaluated dosimetry, biodistribution, and safety of the drug in healthy subjects and patients with heart failure. The trial enrolled 12 participants and was conducted in the United States.
LMI 1195-101 is the specific drug name used in clinical trials. No alternative names have been reported for this investigational compound. It is being studied under this identifier in the context of heart failure research.